10% Owner Catalyst4 Drops $15.3M on MapLight Stock After Positive Schizophrenia Data
MPLT sits 51% above its 52-week low of $9.1 on elevated volume (4.4× avg).
Summary
10% owner Catalyst4, Inc. purchased $15.3 million of MapLight Therapeutics stock in the open market between July 28-30, 2026, following positive Phase 2 schizophrenia trial results.
Key Events · Ownership and Investor Activity · MPLT
-
10% Owner Buys $15.3M in Open Market
Catalyst4, Inc. acquired 1,209,225 shares of MapLight Therapeutics between July 28-30, 2026, at prices ranging from $10.74 to $13.00, totaling $15,314,794.
-
Purchase Follows Positive Phase 2 Data
The buying occurred immediately after MapLight announced positive Phase 2 ZEPHYR trial results for ML-007C-MA in schizophrenia on July 27, 2026, suggesting the investor sees the data as a strong de-risking event.
-
Stake Increased to 20.9 Million Shares
Post-transaction, Catalyst4 holds 20,906,689 shares, representing a significant ownership position in the company.
-
Context: Mixed Recent News Flow
The purchase comes despite a recent CFO departure in June and a Phase 2 miss for ML-004 in autism spectrum disorder, highlighting the investor's focus on the schizophrenia program.
Analysis · MPLT · Life Sciences
Just days after MapLight Therapeutics unveiled positive Phase 2 ZEPHYR trial results for ML-007C-MA in schizophrenia, 10% owner Catalyst4, Inc. stepped into the open market and bought $15.3 million worth of shares over three days. The purchases, executed at prices between $10.74 and $13.00, represent a powerful vote of confidence from a large, non-insider investor—especially notable given the recent mixed clinical data and a CFO departure. While Catalyst4 is not an officer or director, the size of the buy signals strong conviction in the company's pipeline at a critical juncture.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 34.9% of the 1159 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MPLT was trading at $13.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $597.9M. The 52-week trading range was $9.10 to $40.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.